Qualigen Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Michael Poirier
Chief executive officer
US$632.7k
Total compensation
| CEO salary percentage | 81.0% |
| CEO tenure | 7.4yrs |
| CEO ownership | 0.3% |
| Management average tenure | no data |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M
Aug 16Qualigen Therapeutics files mixed shelf offering of up to $150M
Jul 29Qualigen partners Hande Sciences to support its application enabling studies for QN-302
Jul 06Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?
Mar 08
We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate
Nov 23Is Qualigen Therapeutics (NASDAQ:QLGN) In A Good Position To Deliver On Growth Plans?
Apr 05Qualigen nabs additional U.S. patent for ALAN anticancer platform
Dec 15Qualigen Therapeutics EPS misses by $0.61, misses on revenue
Nov 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$633k | US$513k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$18m |
| Jun 30 2023 | n/a | n/a | -US$18m |
| Mar 31 2023 | n/a | n/a | -US$18m |
| Dec 31 2022 | US$728k | US$575k | -US$14m |
| Sep 30 2022 | n/a | n/a | -US$15m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$17m |
| Dec 31 2021 | US$742k | US$518k | -US$18m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$25m |
| Dec 31 2020 | US$5m | US$291k | -US$20m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$20m |
| Mar 31 2020 | n/a | n/a | -US$2m |
| Dec 31 2019 | US$252k | US$252k | -US$1m |
Compensation vs Market: Michael's total compensation ($USD632.70K) is about average for companies of similar size in the US market ($USD667.96K).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
CEO
Michael Poirier (67 yo)
7.4yrs
Tenure
US$632,698
Compensation
Mr. Michael S. Poirier serves as President and Chief Operating Officer at Qualigen Therapeutics, Inc. He has been Chief Executive Officer of Qualigen Therapeutics, Inc. (formerly known as Qualigen, Inc.) s...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.6yrs | US$632.70k | 0.33% $ 6.3k | |
| Independent Director | 3.4yrs | US$46.00k | 0.031% $ 592.3 | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
| Independent Director | 6.9yrs | US$40.00k | 0.029% $ 541.8 | |
| Director | 4yrs | US$16.33k | 0.0064% $ 121.7 | |
| Chair of Scientific Advisory Board | 1.8yrs | no data | no data | |
| Independent Director | 4yrs | US$42.00k | 0% $ 0 | |
| Independent Director | 6.9yrs | US$40.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data |
2.6yrs
Average Tenure
67yo
Average Age
Experienced Board: QLGN's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.